Tradestie Institutional Equity Comparison Engine · Market Close Feb 06, 2026

GBIO vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)

AKRO Overall Winner 6-Pillar Tally: GBIO 1 – 3 AKRO (2 Tie) Matrix Metrics: GBIO 2 – 7 AKRO

As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GBIO vs AKRO
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
TTM Revenue $15M
Forward P/E 7.9x
Beta / 30D Vol 0.80β · 26% Vol
Unified Composite Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $5.61 · SMA50: $5.49
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (GBIO 1 – 3 AKRO)

Columns: Metric · GBIO · AKRO
1. Valuation Multiples GBIO
Forward P/E 7.9x N/M
Trailing P/E 7.9x N/M
PEG Ratio N/M N/M
EV / Revenue 2.5x N/M
2. Growth & Scale AKRO
Revenue Growth (YoY) -78.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15M N/A
Market Cap $38.7M $4.5B
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin -2020.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -80.8% -34.5%
4. Balance Sheet & Cash Flow AKRO
Cash Generation (TTM) -$76M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.51 Book/Sh · -80.8% ROE $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 7.3% (30th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GBIO (2) vs AKRO (7)
Institutional Metric GBIO AKRO Criterion Row Edge
Market Capitalization
Scale
$38.7M $4.5B Larger Scale AKRO
Trailing P/E Ratio
Valuation
7.9x N/M Lower Multiple GBIO
Forward P/E Ratio
Valuation
7.9x N/M Lower Multiple GBIO
Revenue Growth (YoY)
Growth
-78.9% +0.0% Higher Growth AKRO
Operating Margin (TTM)
Profitability
-2020.0% 0.0% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-80.8% -34.5% Higher ROE AKRO
52-Week Range Position
Momentum
62% ($0–$8) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.80β · 26% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
58.8 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
$15M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$76M EBITDA ($7.51 Book/Sh · -80.8% ROE) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GBIO +4.01 pp
GBIO: +5.38% · AKRO: +1.37%
3M Horizon AKRO +36.46 pp
GBIO: -13.98% · AKRO: +22.48%
6M Horizon GBIO +1229.26 pp
GBIO: +1229.15% · AKRO: -0.11%
1Y Horizon AKRO +31.37 pp
GBIO: -36.43% · AKRO: -5.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GBIO vs AKRO. Trailing 12-month operating profitability (GBIO -2020.0% vs AKRO 0.0%) and valuation multiples (GBIO 7.9x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15M
Gross MarginN/A
Op. Margin-2020.0%
ROE / Fwd P/E-80.8% · 7.9x
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GBIO vs AKRO Key Questions & Quantitative Answers

As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Technically, GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure) and AKRO sits in a Markup phase (RSI 67.3, UNCLASSIFIED options structure).

AKRO leads the Growth & Scale pillar: GBIO posts -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GBIO generates $15M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, GBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

GBIO screens cheaper on headline valuation multiples. GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GBIO (-80.8% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 06, 2026. For educational research only; not investment advice.